Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Behind every facility expansion, technology investment, and quality milestone in the CDMO sector is a leadership team making deliberate choices about where to focus, how to grow, and when to take calculated risks.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
A video roundup of the week’s top industry news stories.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
Contract Pharma Stream offers a centralized destination where users can watch expert-led sessions anytime, anywhere
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Privacy or stupidity in biomarker testing?
October 11, 2005
By: Gil Roth
President, Pharma & Biopharma Outsourcing Association
I was all set to write about disaster response and the ways we should prepare for cataclysms both natural and manmade, but another subject came up, so I have to cut that sermon-ette down to a single piece of advice: the more time you spend blaming other people for not helping you, the less time you have to help yourself. What subject could possibly have been more important to me than the opportunity to pontificate about the hurricanes that struck the Gulf Coast and the good and the bad of our responses to them? Longtime readers of this space know about my unhealthy preoccupation with sports, thanks to my repeated attempts at bridging the gap between that world and the Pharma business. Now my favorite pro sport has run headlong into my pro life as we finally achieve the intersection of biomarkers and basketball! Last March, late in the season, Chicago Bulls center Eddy Curry experienced heart arrhythmia before a game. Doctors began testing him, and he was benched for the rest of the season and the playoffs. The tests were inconclusive, and Curry planned to come back this season, angling for a long-term contract before training camp opened. However, the NBA’s insurance company considered him too much of a risk and refused to cover any contract for Curry. Eventually, at the behest of a top cardiologist, the Bulls asked Curry to take a DNA test to see if he was predisposed to hypertrophic cardiomyopathy, a potentially fatal heart condition. This way, the team would know if there was a significant risk both to their investment in Curry (which would’ve added up to around $70 million, given the market for young centers) and to Curry’s investment in the first 22 years of his life. Curry refused to take the test, citing medical privacy issues and advice from his own cardiologist. The NBA commissioner backed up the Bulls’ request for the DNA test, but the players’ association supported Curry, evidently under the logic that the right to die on the basketball court is protected by the union. Or at least that it should be negotiated. The two parties were stuck at an impasse right up until the deadline for offering Curry a one-year deal was about the expire. At that point, the Bulls gave up and traded Curry to New York, where he’s been offered a long-term deal and will undergo standard medical tests, but not the DNA exam for the biomarker that Dr. Maron was concerned with. At the press conference to announce the trade, Bulls general manager John Paxson revealed that if Curry “failed” the DNA test, the Bulls had agreed to pay him $400,000 annually for the next 50 years. It wasn’t real-world, lump-sum dollars, but it was $20 million to carry him into his 70s. So now he can go to New York, play center for the Knicks, and pray that his cardiologist was right. After all, Curry’s people argued, there’s no assurance, even if he does possess that biomarker, that he’ll have a fatal heart attack during the years of his contract. Alan Milstein, a lawyer representing Curry, remarked, “If employers could give employees DNA tests, then they could find out if there’s a propensity for illnesses like cancer, heart disease or alcoholism. They will make personnel decisions based on DNA testing.” Now, I’m all for privacy rights-tattered though they may be-and I don’t want to see an age where biomarkers for long-term diseases are used by employers to discriminate. That said, I also watched the 1993 playoff game in which 27-year-old Celtics forward Reggie Lewis keeled over from hypertrophic cardiomyopathy (he survived that episode, but died a few months later when trying to come back to the Celtics). Eddy Curry wasn’t asking for a $7.50/hour job greeting people at Wal-Mart. He was trying to get guarantees of $70 million or so for demanding physical activity, but was unwilling to assure his employer that he’d be medically fit to, um, survive the contract, much less perform at a high level during its span. Trying to make this kid-who jumped straight to the pros from high school-into a poster boy for genetic discrimination is a near-criminal act. Gil Roth Editor [email protected]
Enter the destination URL
Or link to existing content
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !